MA34771B1 - Formes cristallines - Google Patents

Formes cristallines

Info

Publication number
MA34771B1
MA34771B1 MA36066A MA36066A MA34771B1 MA 34771 B1 MA34771 B1 MA 34771B1 MA 36066 A MA36066 A MA 36066A MA 36066 A MA36066 A MA 36066A MA 34771 B1 MA34771 B1 MA 34771B1
Authority
MA
Morocco
Prior art keywords
varieties
modulation
sensitive
cells
determining
Prior art date
Application number
MA36066A
Other languages
Arabic (ar)
English (en)
Inventor
Lili Feng
Baoqing Gong
Piotr H Karpinski
Liladhar Murlidhar Waykole
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45464892&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA34771(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA34771B1 publication Critical patent/MA34771B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La présente invention concerne des formes cristallines spécifiques de la 5 -chloro-n-(2-isopropoxy-5-méthyl-4-(pipéridin-4-ylphényl)-n-2-(isopropylsulfonyl)phényl)-2,4-diamine. La présente invention concerne en outre des procédés de préparation desdites formes cristallines, des compositions pharmaceutiques comprenant lesdites formes cristallines, et des procédés d'utilisation desdites formes cristallines et des compositions pharmaceutiques pour traiter une maladie.
MA36066A 2010-12-17 2013-06-28 Formes cristallines MA34771B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201061424194P 2010-12-17 2010-12-17
PCT/US2011/065030 WO2012082972A1 (fr) 2010-12-17 2011-12-15 Formes cristallines de la 5-chloro-n2-(2-isopropoxy-5-méthyl-4-pipéridin-4-yl-phényl)-n4[2-(propane-2-sulfonyl)-phényl]-pyrimidine-2,4-diamine

Publications (1)

Publication Number Publication Date
MA34771B1 true MA34771B1 (fr) 2013-12-03

Family

ID=45464892

Family Applications (1)

Application Number Title Priority Date Filing Date
MA36066A MA34771B1 (fr) 2010-12-17 2013-06-28 Formes cristallines

Country Status (35)

Country Link
US (2) US9309229B2 (fr)
EP (3) EP3121171B1 (fr)
JP (1) JP5916752B2 (fr)
KR (4) KR20190022903A (fr)
CN (7) CN114989139A (fr)
AR (2) AR084309A1 (fr)
AU (1) AU2011343775B2 (fr)
BR (1) BR112013015000A2 (fr)
CA (1) CA2821102C (fr)
CL (1) CL2013001723A1 (fr)
CO (1) CO6801792A2 (fr)
CY (2) CY1119474T1 (fr)
DK (2) DK3121171T3 (fr)
EC (1) ECSP13012770A (fr)
ES (3) ES2696526T3 (fr)
GT (1) GT201300153A (fr)
HR (2) HRP20171477T1 (fr)
HU (1) HUE041845T2 (fr)
IL (1) IL226474A (fr)
LT (2) LT2651918T (fr)
MA (1) MA34771B1 (fr)
MX (1) MX338210B (fr)
MY (2) MY164810A (fr)
NZ (1) NZ610713A (fr)
PE (1) PE20140698A1 (fr)
PL (2) PL2651918T3 (fr)
PT (2) PT3121171T (fr)
RS (1) RS57771B1 (fr)
RU (2) RU2599785C3 (fr)
SG (2) SG190856A1 (fr)
SI (2) SI3121171T1 (fr)
TN (1) TN2013000216A1 (fr)
TW (2) TWI576343B (fr)
WO (1) WO2012082972A1 (fr)
ZA (1) ZA201303599B (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG190856A1 (en) * 2010-12-17 2013-07-31 Novartis Ag Crystalline forms of 5-chloro-n2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-n4[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine
BR112015010221B1 (pt) 2012-11-06 2022-09-13 Shanghai Fochon Pharmaceutical Co., Ltd. Inibidores de quinase alk, seus usos, composição farmacêutica, e método para fabricação de medicamento
KR101656382B1 (ko) * 2014-02-28 2016-09-09 한국화학연구원 피리미딘-2,4-디아민 유도체 및 이를 유효성분으로 함유하는 항암용 약학적 조성물
CN105272921A (zh) * 2014-06-09 2016-01-27 江苏奥赛康药业股份有限公司 一种制备Ceritinib的方法及其中间体化合物
CN105294649B (zh) * 2014-07-30 2019-05-14 江苏奥赛康药业股份有限公司 一种Ceritinib化合物及其药物组合物
CN105294650A (zh) * 2014-08-01 2016-02-03 江苏奥赛康药业股份有限公司 一种Ceritinib化合物及其药物组合物
KR102331856B1 (ko) 2014-10-21 2021-11-29 다케다 야쿠힌 고교 가부시키가이샤 결정 형태의 5-클로로-n4-[2-(디메틸포스포릴)페닐]-n2-｛2-메톡시-4-[4-(4-메틸피페라진-1-일)피페리딘-1-일]피리미딘-2,4-디아민
WO2016081538A1 (fr) 2014-11-18 2016-05-26 Teva Pharmaceuticals International Gmbh Formes solides de ceritinib et sels de ceux-ci
CN105601614A (zh) * 2014-11-21 2016-05-25 奥浦顿（上海）医药科技有限公司 一种色瑞替尼晶型及其制备方法
WO2016082795A1 (fr) * 2014-11-28 2016-06-02 苏州晶云药物科技有限公司 Forme cristalline i du ceritinib et son procédé de préparation
CN105622577A (zh) * 2014-11-29 2016-06-01 江苏先声药业有限公司 一种色瑞替尼的新晶型及其制备方法
WO2016108123A2 (fr) * 2014-12-17 2016-07-07 Dr. Reddy’S Laboratories Limited Forme amorphe pure et dispersion solide amorphe de céritinib
WO2016098042A1 (fr) * 2014-12-19 2016-06-23 Novartis Ag Utilisation du céritinib (ldk -378) dans le traitement de troubles médiés par fes ou fer, en particulier des troubles prolifératifs
WO2016098070A1 (fr) 2014-12-19 2016-06-23 Novartis Ag Forme cristalline de la 5-chloro-n2-(2-isopropoxy-5-méthyl-4-pipéridin-4-yl-phényl)-n4-[2-(propane-2-sulfonyl)-phényl]-pyrimidine-2,4-diamine
WO2017016529A1 (fr) 2015-07-28 2017-02-02 Zentiva, K.S. Formes solides de ceritinib base libre
CN105061397B (zh) * 2015-08-07 2018-01-02 武汉英普瑞医药科技有限公司 一种色瑞替尼的c型晶型及其制备方法与应用
CN106699743B (zh) 2015-11-05 2020-06-12 湖北生物医药产业技术研究院有限公司 嘧啶类衍生物及其用途
WO2017152858A1 (fr) * 2016-03-11 2017-09-14 苏州晶云药物科技有限公司 Forme cristalline de céritinib et procédé pour sa préparation
WO2017158619A1 (fr) 2016-03-15 2017-09-21 Natco Pharma Limited Procédé modifié pour la préparation de céritinib et de forme amorphe de céritinib
JP2019196359A (ja) * 2019-06-17 2019-11-14 ノバルティス アーゲー ピリミジン誘導体およびそれらの中間体を調製する化学的方法
GB201915618D0 (en) 2019-10-28 2019-12-11 Univ Oslo ALK inhibitors for treatment of ALK-negative cancer and antibody-mediated diseases
EP4092021A4 (fr) * 2020-01-17 2023-01-25 Shandong Xuanzhu Pharma Co., Ltd. Forme cristalline d'un inhibiteur de kinase du lymphome anaplasique polycyclique

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
CA2533320A1 (fr) * 2003-08-15 2006-02-24 Novartis Ag 2, 4-pyrimidine diamines utiles dans le cadre du traitement de maladies neoplasiques, de troubles inflammatoires et de troubles du systeme immunitaire
GB0419161D0 (en) * 2004-08-27 2004-09-29 Novartis Ag Organic compounds
MX2009006081A (es) * 2006-12-08 2009-06-17 Irmc Llc Compuestos y composiciones como inhibidores de cinasa de proteina.
SI2091918T1 (sl) * 2006-12-08 2015-01-30 Irm Llc Spojine in sestavki kot inhibitorji protein-kinaze
KR101174201B1 (ko) * 2007-08-28 2012-08-16 아이알엠 엘엘씨 키나제 억제제로서의 2-비페닐아미노-4-아미노피리미딘 유도체
WO2009032694A1 (fr) * 2007-08-28 2009-03-12 Dana Farber Cancer Institute Pyrimidine substituée par amino, dérivés de pyrollopyridine et de pyrazolopyrimidine utilisés en tant qu'inhibiteurs de la kinase et dans le traitement de troubles prolifératifs et de maladies liées à l'angiogenèse
CA2720946C (fr) 2008-04-07 2013-05-28 Irm Llc Composes et compositions comme inhibiteurs de la proteine kinase
HUE035029T2 (en) * 2008-05-21 2018-03-28 Ariad Pharma Inc Kinase inhibitor phosphorus derivatives
WO2010142766A2 (fr) * 2009-06-10 2010-12-16 Cellzome Limited Dérivés de pyrimidine comme inhibiteurs de la zap-70
TWI481607B (zh) 2009-12-17 2015-04-21 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑的２－芳基咪唑衍生物
NZ612788A (en) 2010-12-17 2015-10-30 Reata Pharmaceuticals Inc Pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators
SG190856A1 (en) * 2010-12-17 2013-07-31 Novartis Ag Crystalline forms of 5-chloro-n2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-n4[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine
EP2651219A2 (fr) 2010-12-17 2013-10-23 E.I. Du Pont De Nemours And Company Amides azocycliques fongicides
CN105294650A (zh) 2014-08-01 2016-02-03 江苏奥赛康药业股份有限公司 一种Ceritinib化合物及其药物组合物
WO2016081538A1 (fr) 2014-11-18 2016-05-26 Teva Pharmaceuticals International Gmbh Formes solides de ceritinib et sels de ceux-ci
DE112015005255B4 (de) 2014-11-21 2023-10-26 Joyson Safety Systems Acquisition Llc Airbagmodul
CN105622577A (zh) 2014-11-29 2016-06-01 江苏先声药业有限公司 一种色瑞替尼的新晶型及其制备方法
JP2017537927A (ja) 2014-12-04 2017-12-21 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ がん（骨髄腫）を処置するための抗ｃｓ１および抗ｐｄ１抗体の併用
WO2016098070A1 (fr) 2014-12-19 2016-06-23 Novartis Ag Forme cristalline de la 5-chloro-n2-(2-isopropoxy-5-méthyl-4-pipéridin-4-yl-phényl)-n4-[2-(propane-2-sulfonyl)-phényl]-pyrimidine-2,4-diamine
WO2017016529A1 (fr) 2015-07-28 2017-02-02 Zentiva, K.S. Formes solides de ceritinib base libre
CN105061397B (zh) 2015-08-07 2018-01-02 武汉英普瑞医药科技有限公司 一种色瑞替尼的c型晶型及其制备方法与应用

Also Published As

Publication number Publication date
CO6801792A2 (es) 2013-11-29
US20160175305A1 (en) 2016-06-23
MX2013006952A (es) 2013-07-15
TWI576343B (zh) 2017-04-01
ECSP13012770A (es) 2013-10-31
CN104262324A (zh) 2015-01-07
DK3121171T3 (en) 2018-12-10
CY1121017T1 (el) 2019-12-11
EP3453708A1 (fr) 2019-03-13
IL226474A (en) 2016-03-31
PT2651918T (pt) 2017-10-17
DK2651918T3 (en) 2017-10-23
ES2643016T3 (es) 2017-11-21
PL2651918T3 (pl) 2017-12-29
PT3121171T (pt) 2018-11-27
CN107056751A (zh) 2017-08-18
LT3121171T (lt) 2018-11-12
KR20190022903A (ko) 2019-03-06
AU2011343775B2 (en) 2015-12-03
US20130274279A1 (en) 2013-10-17
MY177742A (en) 2020-09-23
RS57771B1 (sr) 2018-12-31
ES2905973T3 (es) 2022-04-12
JP5916752B2 (ja) 2016-05-11
ZA201303599B (en) 2014-02-26
EP3453708B8 (fr) 2022-03-16
SG190856A1 (en) 2013-07-31
WO2012082972A1 (fr) 2012-06-21
MY164810A (en) 2018-01-30
HUE041845T2 (hu) 2019-05-28
CN106831716A (zh) 2017-06-13
KR20200039021A (ko) 2020-04-14
AR084309A1 (es) 2013-05-08
CA2821102C (fr) 2019-06-11
EP2651918B1 (fr) 2017-07-12
KR102325775B1 (ko) 2021-11-12
EP3453708B1 (fr) 2021-10-27
TN2013000216A1 (en) 2014-11-10
RU2016136823A3 (fr) 2020-02-06
CN106008462A (zh) 2016-10-12
HRP20171477T1 (hr) 2017-11-17
ES2696526T3 (es) 2019-01-16
RU2599785C2 (ru) 2016-10-20
RU2746159C2 (ru) 2021-04-08
JP2013545812A (ja) 2013-12-26
KR20180032680A (ko) 2018-03-30
TW201629021A (zh) 2016-08-16
EP2651918A1 (fr) 2013-10-23
GT201300153A (es) 2014-06-09
SI2651918T1 (sl) 2017-10-30
CN114989139A (zh) 2022-09-02
EP3121171B1 (fr) 2018-08-15
EP3121171A1 (fr) 2017-01-25
PE20140698A1 (es) 2014-06-11
RU2016136823A (ru) 2018-12-11
TW201307299A (zh) 2013-02-16
CN112125884A (zh) 2020-12-25
AU2011343775A1 (en) 2013-07-18
CY1119474T1 (el) 2018-04-04
SI3121171T1 (sl) 2018-11-30
IL226474A0 (en) 2013-07-31
RU2013132947A (ru) 2015-01-27
RU2599785C3 (ru) 2019-04-24
CN103282359A (zh) 2013-09-04
AR122395A2 (es) 2022-09-07
BR112013015000A2 (pt) 2016-08-09
CA2821102A1 (fr) 2012-06-21
NZ610713A (en) 2014-10-31
LT2651918T (lt) 2017-10-10
KR20130130022A (ko) 2013-11-29
SG10201510082XA (en) 2016-01-28
TWI576344B (zh) 2017-04-01
CL2013001723A1 (es) 2013-12-27
PL3121171T3 (pl) 2019-01-31
MX338210B (es) 2016-04-07
US9309229B2 (en) 2016-04-12
HRP20181737T1 (hr) 2018-12-28

Similar Documents

Publication Publication Date Title
MA34771B1 (fr) Formes cristallines
MA32351B1 (fr) Derives d'aminodihydrothiazine a titre d'inhibiteurs de bace pour le traitement de la maladie d'alzheimer
TW200634006A (en) Tetrahydroquinoline analogues as muscarinic agonists
MA33450B1 (fr) Dérivés d'oxazine et leur utilisation en tant qu'inhibiteurs de bace pour le traitement de troubles neurologiques
MA34299B1 (fr) Dérivés d'aminopyrimidine au titre de modulateurs de lrrk2
MA31433B1 (fr) Inhibiteurs de la p70 s6 kinase
EA201100691A1 (ru) Антагонисты рецепторов лизофосфатидной кислоты
WO2007120689A3 (fr) Procédés d'utilisation du récepteur gpr119 pour identifier des composés utiles pour augmenter la masse osseuse chez un individu
MA33492B1 (fr) Inhibiteurs de bace
EA201001680A1 (ru) Соединения бензолсульфонамидтиазола и оксазола
EA200970612A1 (ru) Производные индола в качестве агонистов рецептора s1p1
MA30672B1 (fr) Utilisation de derives de l'azabicyclo hexane
EA201070148A1 (ru) Соединения и способы модулирования фарнезоидного рецептора x (fxr)
EA200800727A1 (ru) Введение ингибиторов дипептидилпептидазы
MX2009007337A (es) Indazoles sustituidos con 5-piridinona.
WO2006102308A3 (fr) Antagonistes de bêta-lactamyl vasopressine v1b
ATE486601T1 (de) Verwendung von 3- (4-amino-1-oxo-1,3-dihydro- isoindol-2-yl)-piperidin--2,6-dion zur behandlung von mantelzelllymphomen
MA35716B1 (fr) Formulations pharmaceutiques
EA200970532A1 (ru) Фумаратная соль (альфа s, бета r)-6-бром-альфа-[2-(диметиламино)этил]-2-метокси-альфа-1-нафталенил-бета-фенил-3-хинолинэтанола
WO2009089263A3 (fr) Nouvelles compositions et procédés d'utilisation
MY167575A (en) Heterocyclic compounds and use thereof as modulators of type iii receptor tyrosine kinases
MA33679B1 (fr) Derives de 2-oxo-1-pyrrolidinyle imidazothiadiazole
MA39163A1 (fr) Forme cristalline de (s)-(2-(6-chloro-7-methyl-1h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1 -yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone et utilisation de celle-ci en tant qu'antagonistes des recepteurs de l'orexine
MA33839B1 (fr) Compositions et procédés destinés à diagnostiquer et à traiter des tumeurs
MA39164A1 (fr) Forme de sel cristalline de (s)-(2-(6-chloro-7-méthyl-1 h-benzo[d]imidazol- 2-yl)-2-méthylpyrrolidin-1-yl)(5-méthoxy-2-(2h-1,2,3-triazol-2-yl)phényl)méthanone comme antagoniste des récepteurs à l'oréxine